01 - 05 June 2019
Lisbon, Portugal

Industry Programme

Company Sponsored Symposia


Sunday, 2 June 2019

 

Company Sponsored Symposium (CSS 1)
Allergy Therapeutics plc.
10:30 – 12:00, Hall 5
Allergy Logo transparent

Transforming Allergy Treatment
Chair: Dolores Hernández F. de Rojas, Spain

Evolution of Allergen Immunotherapy
Speaker: Lawrence DeBuske, United States 

Venom Immunotherapy
Speaker: Jörg Kleine-Tebbe, Germany

The hygiene Hypothesis; stepping into the spotlight
Speaker: Erika Jensen-Jarolim, Austria


Company Sponsored Symposium (CSS 2)
Aimmune Therapeutics
12:05 – 13:25, Hall 8
Aimmune RGB 

111 years of oral immunotherapy: Progress in the development of treatment for food allergy using OI
Chair: Margitta Worm, Germany

Chair’s Welcome and Introduction: EU Anaphylaxis Registry – Update
Speaker: Margitta Worm, Germany

Recent Research Advances in the Management of Peanut Allergy
Speaker: Pablo Rodríguez del Río, Spain

OIT Experience in France
Speaker: Amandine Divaret-Chauveau, France

Q&A Panel Discussion


Company Sponsored Symposium (CSS 3)
Novartis
13:30 – 15:00, Hall 5
novartis logo pos rgb

The treatment gap in asthma and morbidities: advances in targeting IgE and DP2receptor
Chair: Marc Humbert, France

Welcome and introduction
Speaker: Marc Humbert, France

Advances in targeting IgE

An overview of the biology of targeting IgE and its clinical translation to asthma treatment
Speaker: Marc Humbert, France

Nasal polyps and allergic rhinitis: The role of targeting IgE
Speaker: Martin Wagenmann, Germany

What is the role of IgE in chronic urticaria?
Speaker: Marcus Maurer, Germany

Advances in targeting the DP2receptor

Overview of the DP2receptor pathway and its role in inflammation
Speaker: Christian Domingo, Spain

Chair-led expert discussion and audience Q&A

Summary and close
Speaker: Marc Humbert, France

Company Sponsored Symposium (CSS 4)
Sanofi Genzyme and Regeneron
15:30 – 17:00, Hall 5
SANOFI GENZYME REGENERON logo 600x200 04

Exploring the Multiple Facets of Type 2 Inflammation in Uncontrolled Persistent Asthma: A New Approach in Asthma Management

Learning objectives:
This interactive symposium will explore the impact of type 2 inflammation in patients with uncontrolled persistent asthma, including the underlying pathophysiology, benefits and limitations of inflammatory biomarkers, and the challenges faced by physicians when selecting a biologic treatment strategy—using case studies, panel discussion, and Q&A to consolidate learnings. The latest clinical data on biologics will be presented, focusing on the key asthma control goals of reducing exacerbations and oral corticosteroid (OCS) use, and improving lung function and quality of life.


Chair: Eric Bateman, South Africa

Welcome and Introduction
Speaker: Eric Bateman, South Africa

Type 2 Inflammation in Asthma: Understanding Pathophysiology and the Role of Biomarkers
Speaker: Klaus Rabe, Germany

Current and New Treatment Options for Uncontrolled Persistent Asthma with Type 2 Inflammation
Speaker: Ian Pavord, United Kingdom

Importance of Reducing OCS Use in Patients with Asthma
Speaker: Klaus Rabe, Germany

Case-based Discussions—Unravelling Asthma Phenotypes and Endotypes: New Considerations for Patient Identification and Biologic Selection – All Faculty

Closing Remarks and Q&A – All Faculty
Speaker: Eric Bateman, South Africa 


Monday, 3 June 2019

 

Company Sponsored Symposium (CSS 5)
ALK
10:45 – 12:15, Hall 14
ALK Logo
Predicting response to SQ SLIT-tablets: Advances in technology and use of biomarkers
Chair: Victoria Cardona, Spain

AIT formulation - does it matter?
Speaker: Natalija Novak, Germany

Immunological cross-reactivity and clinical relevance of the SQ tree SLIT-tablet
Speaker: Tilo Biedermann, Germany

Can we use biomarkers to predict AIT response in allergic asthma?
Speaker: Eugene Bleecker, United States

Clinical relevance of immunology in AIT - your questions answered
Speaker: Stephen Durham, United Kingdom
 

Company Sponsored Symposium (CSS 6)
Mylan 
12:20 – 13:40, Hall 4
Mylan
New targets in AR Treatment: Asthma & Nasal Hyper responsiveness
Chair: Nikolaos Papadopoulos, United Kingdom

Introduction
Speaker: Nikolaos Papadopoulos, United Kingdom

May I introduce?! - Nasal Hyper Responsiveness
Speaker: Peter Hellings, Belgium

New data on comorbid Asthma patients: AR treatment improves Asthma outcomes
Speaker: David Price, Australia

Reliever medication for AIT Patients
Speaker: Claus Bachert, Belgium

The new targets in the new ARIA guideline
Speaker: Jean Bousquet, France

Conclusion - All

 
Company Sponsored Symposium (CSS 7)
HAL Allergy 
13:45 – 15:15, Hall 8
hal allergy
Opening a new world for allergy
Chair: Ronald van Ree, Netherlands
Chair: Dirk-Jan Opstelten, Netherlands


Food allergy treatment: Current State and Future Options
Speaker: James R. Baker Jr. , United States

Mite AIT: What's next?
Speaker: Moisés Antonio Calderón, United Kingdom

Allergy Therapy and Prevention in 2030
Speaker: Johann Christian Virchow, Germany

Wrap-Up
Speaker: Ronald van Ree, Netherlands 

 
Company Sponsored Symposium (CSS 8)
Allergopharma GmbH & Co. KG 
15:45 – 17:15, Hall 8
Allergopharma Logo 2018
FASIT* - we can work it out! -*Future of the Allergists and Specific Immunotherapy
Chair: Oliver Pfaar, Germany
Chair: Stephen Durham, United Kingdom


AIT - ready to become standard asthma treatment?
Speaker: Graham Roberts, United Kingdom

AIT in rhinitis - what is the regulators' view?
Speaker: Vera Mahler, Germany

AIT in 2024 - where is the journey taking us?
Speaker: Carsten Schmidt-Weber, Germany 


Tuesday, 4 June 2019


Company Sponsored Symposium (CSS 9)
Thermo Fisher Scientific
10:30 - 12:00, Hall 14
logo thermofisher
Asthma and Food Allergy Management using Cutting Edge CRD Technology

Learning objectives:
To improve the knowledge among health care providers and scientists about the role of IgE antibodies in respiratory allergy and food allergy.
To inform the latest scientific news about allergen components with focus on tree nuts, sesame, red meat, house dust mite, grass pollen, and dog and cat dander.
To present the state of the art knowledge about how allergen sensitization patterns can be used as an aid in clinical diagnosis of allergy and asthma.


Chair: Paolo Matricardi, Germany

Molecular allergology in asthma - The use of mite and grass pollen components
Speaker: Paolo Matricardi, Germany

New diagnostic tools for allergy to furry animals and red meat
Speaker: Marianne van Hage, Sweden

Allergen components in pediatric food allergy diagnosis
Speaker: Anna Nowak-Wegrzyn, United States

Allergen microarrays and sensitization algorithms for prediction of asthma
Speaker: Adnan Custovic, United Kingdom

Summary and future directions
Speaker: Paolo Matricardi, Germany 

 
Company Sponsored Symposium (CSS 10)
Stallergenes Greer
12:05 – 13:25, Hall 4
regulatory with tagline cmyk
Expanding options in house dust mite AIT - Optimizing individual patients outcomes

Learning objectives:
Share specific evidences that public health burden of chronci allergic disease is increasing in terms of prevalence, complexity and severity.
Symptoms of HDM Associated AR negatively affect patients’ including children health-related quality of life. patients with uncontrolled AR are
at risk of developping allergic asthma, failing in their personal and professional projetcs AR strengthen the scientific evidence that: successful
treatment of symptoms with AIT improves the HRQL but also modify the course of the disease, by showing long-term benefits and protection
an important consideration for parents whose children's AR symptoms are not controlled.  

Chair: Thomas Casale, United States
Chair: Moisés Calderón, United Kingdom

Burden of HDM allergic respiratory diseases
Speaker: Petra Zieglmayer, Austria

Precision medicine to optimize patient outcomes
Speaker: Philippe Gevaert, Belgium

The 300IR "solution" and future trends
Speaker: Pascal Demoly, France 
 

Company Sponsored Symposium (CSS 11) 
AstraZeneca UK Ltd
13:30 – 15:00, Hall 9
astrazeneca
Optimising the Management of Patients with Severe Eosinophilic Asthma: The Role of Precision Medicine
Chair: Sameer Mathur, United States

Welcome and Introductions

Asthma Heterogeneity: Understanding the Eosinophilic Phenotype
Speaker: João Almeida Fonseca, Portugal

Emerging Evidence and the Evolving Therapeutic Landscape
Speaker: Stephanie Korn, Germany

Insights From Patient Cases
Speaker: Sameer Mathur, United States

Panel Discussion and Audience Q&A
 

 
Company Sponsored Symposium (CSS 12)
Novartis  
15:30 – 17:00, Hall 8
novartis logo pos rgb
The many faces of mastocytosis, from interdisciplinary diagnosis to treatment strategies, and an insight into the patient’s journey
Chair: Frank Siebenhaar, Germany

Welcome
Speaker: Frank Siebenhaar, Germany

Mastocytosis - a disease with many faces
Speaker: Frank Siebenhaar, Germany

An interdisciplinary approach and diagnostic measures for mastocytosis
Speaker: Sigurd Broesby-Olsen, Denmark

Clinical hallmarks and therapeutic strategies for advanced systemic mastocytosis
Speaker: Andreas Reiter, Germany

Insights into the patient's journey - experience from patient groups
Speaker: Jess Hobart, United Kingdom

Insights into the patient's journey - experience from patient groups
Speaker: Andrew Dugdale, United Kingdom

Closing remarks
Speaker: Frank Siebenhaar, Germany

Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel